MedlinePlus. What is the difference between precision medicine and personalized medicine? What about pharmacogenomics? https://medlineplus.gov/genetics/understanding/precisionmedicine/precisionvspersonalized/ (2022).

Tsimberidou, A. M. et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00002 (2017).

Christofyllakis, K. et al. Cost-effectiveness of precision cancer medicine — current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol. Clin. Oncol. 16, 21 (2022).

Article  PubMed  Google Scholar 

Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res. 18, 6373–6383 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Hoff, D. D. et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877–4883 (2010).

Article  Google Scholar 

Tsimberidou, A. M. et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin. Cancer Res. 20, 4827–4836 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsimberidou, A. M. et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J. Hematol. Oncol. 12, 145 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larson, K. L. et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis. Oncol. https://doi.org/10.1200/PO.20.00495 (2021).

Luthra, R. et al. A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors. J. Mol. Diagn. 19, 255–264 (2017).

Article  CAS  PubMed  Google Scholar 

Lih, C. J. et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial. J. Mol. Diagn. 19, 313–327 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Goswami, R. S. et al. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. Am. J. Clin. Pathol. 145, 222–237 (2016).

Article  PubMed  Google Scholar 

Ramani, N. S. et al. Factors impacting clinically relevant RNA fusion assays using next-generation sequencing. Arch. Pathol. Lab. Med. 145, 1405–1412 (2021).

Article  CAS  PubMed  Google Scholar 

Jennings, L. J. et al. Guidelines for validation of next-generation sequencing-based oncology panels: a Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J. Mol. Diagn. 19, 341–365 (2017).

Article  PubMed  Google Scholar 

Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4–23 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foundation Medicine. FoundationOne CDx. https://www.foundationmedicine.com/test/foundationone-cdx (2023).

TEMPUS. Genomic Profiling. https://www.tempus.com/oncology/genomic-profiling/xt-xr/ (2023).

CARIS LIFE SCIENCES. Molecular Profiling. https://www.carislifesciences.com/products-and-services/molecular-profiling/testing-menu/ (2023).

Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L. & Siu, L. L. Molecular profiling for precision cancer therapies. Genome Med. 12, 8 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Galuppini, F. et al. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int. 19, 209 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133–150 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2020).

Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).

Article  CAS  PubMed  Google Scholar 

Gelsomino, F., Barbolini, M., Spallanzani, A., Pugliese, G. & Cascinu, S. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat. Rev. 51, 19–26 (2016).

Article  CAS  PubMed  Google Scholar 

Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073–2087.e3 (2010).

Article  CAS  PubMed  Google Scholar 

Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11–19 (2020).

Article  CAS  PubMed  Google Scholar 

Le, D. T. et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur. J. Cancer 186, 185–195 (2023).

Article  CAS  PubMed  Google Scholar 

O’Malley, D. M. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J. Clin. Oncol. 40, 752–761 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929–938 (2022).

Article  CAS  PubMed  Google Scholar 

Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

Article  CAS  PubMed  Google Scholar 

Yoshino, T. et al. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Cancer Sci. 114, 1026–1036 (2023).

Article  CAS  PubMed  Google Scholar 

Oaknin, A. et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J. Immunother. Cancer 10, e003777 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Oaknin, A. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 6, 1766–1772 (2020).

Article  PubMed  Google Scholar 

Oaknin, A. et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-3915 (2023).

Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J. Clin. Oncol. 40, 161–170 (2022).

Article  CAS  PubMed  Google Scholar 

FoundationOne CDx. Technical Information F1CDx. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S029C.pdf (2020).

U.S. Food and Drug Administration. VENTANA: Ventana Anti-MLH1 (M1) Mouse Monoclonal Primary Antibody. https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210001D.pdf (2022).

U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/site Agnostic Indication. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (2017).

MERCK. FDA Converts to Full Approval Indication for KEYTRUDA® (Pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors. https://www.merck.com/news/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient/ (2023).

U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors (2023).

Lebofsky, R. et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol. Oncol. 9, 783–790 (2015).

Article  CAS  PubMed  Google Scholar 

Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A. & Pinto, C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1–8 (2018).

Article  CAS  PubMed  Google Scholar 

Zill, O. A. et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin. Cancer Res. 24, 3528–3538 (2018).

Article  CAS  PubMed  Google Scholar 

Polivka, J. Jr., Pesta, M. & Janku, F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet. Expert Rev. Mol. Diagn. 15, 1631–1644 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer — a survey. Biochim. Biophys. Acta 1775, 181–232 (2007).

CAS  PubMed  Google Scholar